Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo.
Chen B, Roy SG, McMonigle RJ, Keebaugh A, McCracken AN, Selwan E, Fransson R, Fallegger D, Huwiler A, Kleinman MT, Edinger AL, Hanessian S. Chen B, et al. Among authors: hanessian s. ACS Chem Biol. 2016 Feb 19;11(2):409-14. doi: 10.1021/acschembio.5b00761. Epub 2015 Dec 14. ACS Chem Biol. 2016. PMID: 26653336 Free PMC article.
Effects of stereochemistry, saturation, and hydrocarbon chain length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutrient transporter down-regulation, vacuolation, and cell death.
Perryman MS, Tessier J, Wiher T, O'Donoghue H, McCracken AN, Kim SM, Nguyen DG, Simitian GS, Viana M, Rafelski S, Edinger AL, Hanessian S. Perryman MS, et al. Among authors: hanessian s. Bioorg Med Chem. 2016 Sep 15;24(18):4390-4397. doi: 10.1016/j.bmc.2016.07.038. Epub 2016 Jul 18. Bioorg Med Chem. 2016. PMID: 27475534
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
McCracken AN, McMonigle RJ, Tessier J, Fransson R, Perryman MS, Chen B, Keebaugh A, Selwan E, Barr SA, Kim SM, Roy SG, Liu G, Fallegger D, Sernissi L, Brandt C, Moitessier N, Snider AJ, Clare S, Müschen M, Huwiler A, Kleinman MT, Hanessian S, Edinger AL. McCracken AN, et al. Among authors: hanessian s. Leukemia. 2017 Mar;31(3):669-677. doi: 10.1038/leu.2016.244. Epub 2016 Aug 30. Leukemia. 2017. PMID: 27573555 Free PMC article.
Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways.
Kim SM, Roy SG, Chen B, Nguyen TM, McMonigle RJ, McCracken AN, Zhang Y, Kofuji S, Hou J, Selwan E, Finicle BT, Nguyen TT, Ravi A, Ramirez MU, Wiher T, Guenther GG, Kono M, Sasaki AT, Weisman LS, Potma EO, Tromberg BJ, Edwards RA, Hanessian S, Edinger AL. Kim SM, et al. Among authors: hanessian s. J Clin Invest. 2016 Nov 1;126(11):4088-4102. doi: 10.1172/JCI87148. Epub 2016 Sep 26. J Clin Invest. 2016. PMID: 27669461 Free PMC article.
Design, synthesis and anticancer activity of constrained sphingolipid-phenoxazine/phenothiazine hybrid constructs targeting protein phosphatase 2A.
Garsi JB, Vece V, Sernissi L, Auger-Morin C, Hanessian S, McCracken AN, Selwan E, Ramirez C, Dahal A, Romdhane NB, Finicle BT, Edinger AL. Garsi JB, et al. Among authors: hanessian s. Bioorg Med Chem Lett. 2019 Sep 15;29(18):2681-2685. doi: 10.1016/j.bmcl.2019.07.023. Epub 2019 Jul 19. Bioorg Med Chem Lett. 2019. PMID: 31383588 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33431118
201 results